Medicina,
Journal Year:
2023,
Volume and Issue:
45(4), P. 621 - 626
Published: Dec. 31, 2023
Precision
oncology,
defined
as
molecular
profiling
of
tumors
to
identify
targetable
alterations,
is
rapidly
developing,
and
has
entered
the
mainstream
clinical
practice.
Genomic
testing
involves
stakeholders
workingnin
a
coordinated
fashion
deliver
high-quality
tissue
samples
laboratories,
where
appropriate
next-generation
sequencing
(NGS)
analysis
leads
actionable
results.
Clinicians
should
be
familiar
with
types
genomic
variants
reported
by
laboratory
technology
used
determine
effects,
including
limitations
current
methodologies
reports.
results
are
best
interpreted
multidisciplinary
input
reduce
uncertainty
in
recommendations
relating
documented
variant
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 11, 2024
Abstract
Integrating
functional
proteomics
and
next-generation
sequencing
(NGS)
offers
a
comprehensive
approach
to
unraveling
the
molecular
intricacies
of
breast
cancer.
This
study
investigates
interplay
between
genomic
alterations
protein
expression
in
Taiwanese
cancer
patients.
By
analyzing
61
samples
using
tandem
mass
tag
(TMT)
labeling
spectrometry,
coupled
with
whole-exome
(WES)
or
targeted
sequencing,
we
identified
key
genetic
mutations
their
impact
on
expression.
Notably,
pathogenic
variants
BRCA1,
BRCA2,
PTEN,
PIK3CA
were
found
be
clinically
relevant,
potentially
guiding
therapy
decisions.
Additionally,
discovered
trans
correlations
specific
gene
(FANCA,
HRAS,
PIK3CA,
MAP2K1,
JAK2)
22
proteins,
suggesting
potential
mechanisms
underlying
development
progression.
These
findings
highlight
power
integrating
NGS
identify
therapeutic
targets
enhance
personalized
medicine
strategies
for
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 9, 2024
Single-cell
RNA
sequencing
(scRNA-seq)
has
revolutionized
cell
biology
by
enabling
the
profiling
of
transcriptomes
at
a
single-cell
resolution,
leading
to
important
discoveries
that
have
advanced
our
understanding
cellular
and
tissue
heterogeneity,
developmental
trajectories,
disease
progression.
Despite
these
advances,
scRNA-seq
is
limited
measuring
transcriptome
providing
partial
view
function.
To
address
this
limitation,
multimodal
assays
emerged,
allowing
for
simultaneous
measurement
expression
protein.
Intracellular
Transcriptomic
Protein
Sequencing
(InTraSeq),
novel
technology
described
here,
enables
concurrent
mRNA,
surface
markers,
cytoplasmic
proteins,
nuclear
proteins
within
individual
cells
through
oligo-barcoded
antibodies.
This
method
offers
comprehensive
approach
studying
function
combining
protein
from
same
sample
utilizing
relatively
simple
protocol.
The
InTraSeq
researchers
expand
their
critical
intracellular
including
post-translational
modifications
(PTMs)
transcription
factors,
identification
subtypes
states
may
be
obscured
RNA-based
analyses
alone.
particularly
valuable
in
heterogeneity
populations
identifying
distinct
functional
states.
In
report,
we
used
characterize
complex
regulatory
mechanisms
during
Th17
differentiation.
We
simultaneously
profiled
over
85,000
cells,
capturing
transcriptional
changes,
changes
dynamics
signaling
pathways
high
resolution.
Our
results
revealed
insights
into
differentiation,
key
factors
target
genes.
By
extra
intra-cellular
PTMs,
processes
mechanisms.
Cells,
Journal Year:
2024,
Volume and Issue:
13(24), P. 2126 - 2126
Published: Dec. 22, 2024
Advanced
triple-negative
breast
cancer
(TNBC)
has
poorer
outcomes
due
to
its
aggressive
behavior
and
restricted
therapeutic
options.
While
therapies
like
checkpoint
inhibitors
PARP
offer
some
benefits,
chemotherapy
remains
ineffective
beyond
the
first
line
of
treatment.
Antibody–drug
conjugates
(ADCs)
sacituzumab
govitecan-hziy
(SG)
represent
a
significant
advancement.
SG
combines
SN-38,
an
irinotecan
derivative,
with
Trop-2-targeting
antibody
via
pH-sensitive
linking
moiety,
achieving
good
drug:antibody
ratio.
In
phase
I-II
study
involving
metastatic
TNBC
(mTNBC)
individuals,
achieved
overall
response
rate
33.3%
median
period
7.7
months.
The
III
ASCENT
trial
demonstrated
SG’s
efficacy
in
relapsed
or
refractory
TNBC,
improving
progression-free
survival
compared
chemotherapy.
Common
side
effects
include
neutropenia,
nausea,
fatigue.
This
article
highlights
clinical
potential,
pharmacokinetics,
safety
profile,
resistance
mechanisms
along
key
ongoing
trials,
emphasizing
role
managing
mTNBC,
especially
third-line
therapy.
review
also
discusses
current
strategies
for
adverse
reactions
sequencing
ADC
treatments
practice,
predicted
basis
resistance.
optimal
relative
other
ADCs,
such
as
trastuzumab
deruxtecan
T-DXd,
evolving
question,
newer
agents
distinct
action
profiles
enter
field.
Further
research
is
essential
establish
evidence-based
addressing
disease
progression
post-ADC
Medicina,
Journal Year:
2023,
Volume and Issue:
45(4), P. 621 - 626
Published: Dec. 31, 2023
Precision
oncology,
defined
as
molecular
profiling
of
tumors
to
identify
targetable
alterations,
is
rapidly
developing,
and
has
entered
the
mainstream
clinical
practice.
Genomic
testing
involves
stakeholders
workingnin
a
coordinated
fashion
deliver
high-quality
tissue
samples
laboratories,
where
appropriate
next-generation
sequencing
(NGS)
analysis
leads
actionable
results.
Clinicians
should
be
familiar
with
types
genomic
variants
reported
by
laboratory
technology
used
determine
effects,
including
limitations
current
methodologies
reports.
results
are
best
interpreted
multidisciplinary
input
reduce
uncertainty
in
recommendations
relating
documented
variant
